U.S. Markets closed

Boston Scientific Corporation (BSX)

New York Stock Exchange Consolidated Issue - New York Stock Exchange Consolidated Issue Delayed Price. Currency in USD
Add to watchlist
26.84-0.37 (-1.36%)
At close: 4:01PM EDT

26.78 -0.06 (-0.22%)
After hours: 4:50PM EDT

People also watch
MDTSTJBAXBCRBDX
Full screen
Previous Close27.21
Open27.06
Bid0.00 x 0
Ask0.00 x 0
Day's Range26.71 - 27.17
52 Week Range19.67 - 28.51
Volume3,838,696
Avg. Volume6,018,319
Market Cap36.83B
Beta0.91
PE Ratio (TTM)86.03
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barrons.com8 hours ago

    [$$] Medical Tech Bounces Back in Emerging Markets

    Wells Fargo Securities The median constant currency growth rate of the large-cap medical-tech companies in emerging markets (EM) was around 11% in the second quarter. The high median growth was due to nearly across the board sequential improvements in EM growth, which also drove up the average EM growth from about 9% in the first quarter to about 10% in the second quarter, The median EM growth of the large-cap med-tech companies continues to outpace the overall world-wide organic growth rate of 3.5% in the second quarter. The year-over-year (excluding exchange rates) growth of 3.5% for the large-cap med-tech sector in the quarter was the lowest rate we’ve seen since we began tracking this metric in the calendar first-quarter of 2015.

  • The Wall Street Journal11 hours ago

    [$$] Funding Snapshot: Women's Health Care Provider Channel Medsystems Receives $14.1 Million Series C-1

    Company: Channel Medsystems Inc.

  • Reuters2 days ago

    Medtronic misses revenue estimates, shares dip

    Medical device maker Medtronic Plc on Tuesday reported quarterly revenue fell short of analysts' estimates, hurt by lower sales in its diabetes-related device business. Sales in Medtronic's diabetes business, which sells artificial pancreases, glucose sensors and insulin pumps, fell about 1 percent to $449 million in the first quarter ended July 28. Sales, which were hurt by a temporary supply issue related to the company's glucose monitor sensors, lagged Wall Street analysts' average estimate of $471.3 million, according to BMO Capital Markets.